Fig. 2From: Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinomaOverall survival curve of 115 patients treated with Cyberknife SBRT. 1-yr and 2-yrs OSR were 63.5Â % (54-71.5Â %) and 41.3Â % (31.6-50.6Â %), median survival times was 15Â months (4-25 mos.), While 1-yr and 2-yrs Progression-free survival rate were 42.8Â % (33.0-52.2Â %) and 38.8Â % (29.0-48.4Â %), median progressive-free survival times was 6Â months, respectivelyBack to article page